Biomotion Sciences (SLXN) Key Metrics
SLXN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.2M
- Enterprise value
- −$43,067
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 40.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.30
SLXN key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSLXN returns How much profit the business earns on the capital it uses.
SLXN financial health Debt, liquidity and how easily interest is covered.
SLXN efficiency & capital use Working capital cycle and where the cash goes.
SLXN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SLXN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SLXN key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Share price at fiscal year-end | $19.20 | $301.50 | $1,627.50 | $1,510.50 | $1,452.00 | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | — | — | — | — | −1.3% | — |
| Return on invested capital (ROIC) | — | — | — | — | −1.3% | — |
| Return on assets (ROA) | −236.4% | −405.0% | −67.7% | −5.2% | −1.3% | −151.4% |
| Return on tangible assets | −165.1% | −574.3% | −94.0% | −34.4% | −0.7% | −151.4% |
| Financial health | ||||||
| Total debt | $468,000 | $4.5M | $171,000 | $271,000 | — | — |
| Cash & short-term investments | $6.0M | $1.2M | $4.6M | $8.3M | $38,944 | $51,701 |
| Net debt | −$5.5M | $3.3M | −$4.4M | −$8.0M | −$38,944 | −$51,701 |
| Debt / equity | 0.18 | — | — | — | — | — |
| Debt / assets | 0.06 | 1.57 | 0.03 | 0.03 | — | — |
| Current ratio | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Quick ratio | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Interest coverage | 894.8 | -241.8 | -520.1 | -45.4 | — | — |
| Working capital | $3.9M | −$1.3M | $2.8M | $7.2M | $59,221 | $22,301 |
| Invested capital | −$2.9M | −$685,000 | −$19.9M | −$18.7M | $114.9M | −$221,691 |
| Tangible asset value | $2.6M | −$4.0M | −$12.1M | −$7.1M | $114.9M | −$169,991 |
| Net current asset value | $2.0M | −$4.6M | −$12.3M | −$7.6M | −$101,119 | −$247,689 |
| Capital allocation | ||||||
| Capex / depreciation | 0.64 | 0.88 | 0.27 | 0.70 | — | — |
| Efficiency | ||||||
| Days payables outstanding | 22,369.3 | 9,110.4 | — | — | — | — |
| Payables turnover | 0.02 | 0.04 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $858,000 | $624,000 | $279,500 | $240,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SLXN's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SLXN valuation and financial ratios
It ended the year with $0.5 million of debt and $6.0 million in cash and short-term investments, a net cash position of $5.5 million.
See the SLXN income statement, the SLXN chart for price history, or the SLXN stock overview for the latest quote and news.
SLXN key metrics FAQ
How much debt does Biomotion Sciences have?
Biomotion Sciences had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
What is Biomotion Sciences's current ratio?
Biomotion Sciences's current ratio was 2.41 at the end of fiscal 2025: current assets were 2.41 times current liabilities.